Purnanand D Sarma

Dr. Purnanand Sarma serves as the President and Chief Executive Officer of Immunome. Sarma brings more than 25 years of experience in all aspects of pharmaceutical industry business across multiple R&D platforms, ranging from venture-backed biotechniology start-ups to large cap pharmaceutical companies. He was most recently the President & CEO of Taris Biomedical. In addition to raising more than $100M in equity capital, he also sold one of Taris’ products to Allergan (NYSE:AGN) in a deal worth up to $587M. Prior to TARIS, Sarma was the VP and General Manager of World-wide Drug Delivery Technologies for Cephalon Corporation (NYSE:CEPH). Before joining Cephalon, he spent over 10 years in various capacities at Nektar Therapeutics (NASDAQ:NKTR) and built the entire green field operation of Nektar Therapeutics (India), serving as its first Managing Director. He started his career at SmithKline Beecham after obtaining his PhD in Pharmaceutics from the University of Minnesota and B. Pharm from Andhra University, Visakhapatnam, India. In addition to Vaxess, Sarma also serves as a member of the Board of Immunome Inc., and Ohm Oncology.